Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023)

Denali Therapeutics has reported EBIT Margin over the past 6 years, most recently at 8981.45% for Q3 2023.

  • Quarterly EBIT Margin fell 596133.0% to 8981.45% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 37938.04% through Jun 2024, down 3789045.0% year-over-year, with the annual reading at 59.51% for FY2023, 25465.0% up from the prior year.
  • EBIT Margin was 8981.45% for Q3 2023 at Denali Therapeutics, down from 57.96% in the prior quarter.
  • Over five years, EBIT Margin peaked at 77.02% in Q4 2020 and troughed at 7122000.0% in Q1 2021.
  • The 5-year median for EBIT Margin is 1053.44% (2022), against an average of 387320.48%.
  • Year-over-year, EBIT Margin tumbled -712031174bps in 2021 and then surged 712184220bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 1236.26% in 2019, then soared by 106bps to 77.02% in 2020, then crashed by -900bps to 616.28% in 2021, then plummeted by -71bps to 1053.44% in 2022, then plummeted by -753bps to 8981.45% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBIT Margin are 8981.45% (Q3 2023), 57.96% (Q2 2023), and 343.8% (Q1 2023).